Review: HCT for Patients with AML in First Remission

This review focuses on the clinical evidence on whether individuals with acute myelogenous leukemia (AML) in first remission should undergo an allogeneic hematopoietic cell transplant (HCT) versus receiving post-remission chemotherapy (or both). The authors address four common clinical questions: 1) Do only individuals achieving second remission benefit from a transplant? 2) Is allogeneic HCT the only effective therapy for relapse? 3) Can we accurately predict which individuals with AML in first remission need a transplant? and 4) What is the clinical usefulness of detecting minimal residual disease in patients achieving first remission?

Gale RP, et al. Leukemia

Related Resources